Cancer Communications最新文献

{"title":"Loss of WNT2B Increases Tumor Burden and Malignant Features in Colorectal Cancer.","authors":"Luiz Fernando Silva Oliveira, Yu-Syuan Wu, Sathuwarman Raveenthiraraj, Jaedeok Kwon, Venkata S Dasuri, Comfort Adegboye, Juan Putra, Jorge O Munera, Diana L Carlone, David T Breault, Amy E O'Connell","doi":"10.34133/cancomm.0036","DOIUrl":"10.34133/cancomm.0036","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0036"},"PeriodicalIF":28.4,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148326837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.","authors":"Damien Bruyat, Nicolas Girard, Pierre Heudel, Nicolas Penel, Marie-Cécile Le Deley, Issaga Diallo, Jean-Marie Boher, Christophe Zemmour, Brice Chanez, Anne Madroszyk, Gwenaelle Gravis, Emilien Billon, Aaron Lisberg, Bérénice Collineau, Mathilde Beaufils, Anthony Gonçalves, Manuel Tejeda, Anne-Sophie Chrétien, Philippe Rochigneux","doi":"10.34133/cancomm.0035","DOIUrl":"10.34133/cancomm.0035","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0035"},"PeriodicalIF":28.4,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13273061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.","authors":"Xuezhi Hao, Lin Wang, Yanrong Hao, Yanping Hu, Chun Chen, Bi Chen, Yunchao Huang, Aimin Zang, Yan Wang, Zhendong Chen, Wu Zhuang, Jinsheng Shi, Xiubao Ren, Ligong Nie, Guohua Yu, Feng Luo, Yimin Mao, Xiang Wang, Baolan Li, Yuansong Bai, Jianhua Shi, Hongyan Ni, Xiaoli Hou, Haoyu Yu, Jing Li, Qingyu Wang, Jun Zhu, Yuankai Shi","doi":"10.34133/cancomm.0034","DOIUrl":"10.34133/cancomm.0034","url":null,"abstract":"<p><p><b>Background:</b> ASTRUM-002 met the primary endpoint of progression-free survival (PFS) with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. Here, we report the results of the final survival analysis. <b>Methods:</b> A total of 636 patients with treatment-naïve, locally advanced or metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) without epidermal growth factor receptor (<i>EGFR</i>) or anaplastic lymphoma kinase (<i>ALK</i>)<i>/</i>ROS proto-oncogene 1 receptor tyrosine kinase (<i>ROS1</i>) genetic alterations were randomized 1:1:1 to receive serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Patients and the investigators were blinded to the group assignments. The primary endpoint was blinded independent central review-assessed PFS. Overall survival (OS) was the key secondary endpoint. <b>Results:</b> At the final analysis, median OS was 23.7 (95% confidence interval [CI] 20.5 to 27.5) months, 26.8 (95% CI 21.2 to 30.9) months, and 20.3 (95% CI 16.2 to 24.6) months in groups A (<i>n</i> = 212), B (<i>n</i> = 214), and C (<i>n</i> = 210), respectively. A significant reduction in risk of death for group B compared to group C was observed (hazard ratio [HR] = 0.66, 95% CI 0.52 to 0.83; <i>P</i> < 0.001). A total of 79 (37.6%) patients in group C had crossed over to serplulimab plus HLX04 treatment. Median OS in group C adjusted by the 2-stage model was 14.2 months (95% CI 11.9 to 17.0), corresponding to an adjusted HR of 0.53 (95% CI 0.42 to 0.68; <i>P</i> < 0.001) for group B versus group C. Using the rank-preserving structural failure time model, the adjusted median OS in group C was 17.9 months (95% CI 14.2 to 20.3), with a corresponding adjusted HR of 0.65 (95% CI 0.51 to 0.83; <i>P</i> < 0.001). No statistical difference in median OS for group A compared to group B (HR = 1.12, 95% CI 0.88 to 1.42; <i>P</i> = 0.363) was found. <b>Conclusions:</b> Serplulimab plus chemotherapy significantly prolonged OS and maintained PFS benefit compared to chemotherapy; however, the addition of bevacizumab biosimilar HLX04 did not yield further improvement for the first-line treatment of nsq-NSCLC without <i>EGFR</i> or <i>ALK/ROS1</i> genetic alterations. <b>Trial registration:</b> This trial was registered at ClinicalTrials.gov (NCT03952403, date of registration: 2019 May 14).</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0034"},"PeriodicalIF":28.4,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13250280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>TGFBR1</i>*6A and Risk for Colorectal Cancer.","authors":"Allan M Johansen, Julie T Ziegler, Kojo Agyemang, Michael J Pennison, Hugo Jimenez, Loïc Le Marchand, John L Hopper, Daniel D Buchanan, Antonio Di Cristofano, Wencheng Li, Greg Dyson, Ann G Schwartz, Jennifer L Beebe-Dimmer, Lara Sucheston-Campbell, Asfar S Azmi, Wael Sakr, Ralph B D'Agostino, Carl D Langefeld, Boris C Pasche","doi":"10.34133/cancomm.0033","DOIUrl":"10.34133/cancomm.0033","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0033"},"PeriodicalIF":28.4,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13247310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148216593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of China's Drug Regulatory Reforms on the Development of Anti-Tumor Drugs.","authors":"Ling Tang, Lijia Yuan, Ying Geng, Zhimin Yang, Guo Huang","doi":"10.34133/cancomm.0032","DOIUrl":"10.34133/cancomm.0032","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0032"},"PeriodicalIF":28.4,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer.","authors":"Daan A C Lanser, Niels Heersche, M Benthe Muntinghe-Wagenaar, Ma Ida Mohmaed Ali, Ezgi B Ulas, Evert de Jonge, Esther Oomen-de Hoop, Marthe S Paats, Idris Bahce, Sander Croes, Adrianus J Langen, Lizza E L Hendriks, Anthonie J Wekken, Alwin D R Huitema, Ron H N Schaik, Anne-Marie C Dingemans, G D Marijn Veerman, Ron H J Mathijssen","doi":"10.34133/cancomm.0031","DOIUrl":"10.34133/cancomm.0031","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0031"},"PeriodicalIF":28.4,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to <i>Kras</i> ^G12D Inhibition in Pancreatic Cancer.","authors":"Alessia Caggiano, Antonio Agostini, Diego Iacuone, Lorenzo Priori, Annachiara Esposito, Anna Ceccarelli, Diego Rosa, Davide Pasini, Stefano Ugel, Francesco De Sanctis, Federica Cinti, Claudio Sette, Gian Luca Rampioni Vinciguerra, Clara Dezi, Vincenzo Bronte, Geny Piro, Vincenzo Corbo, Giampaolo Tortora, Carmine Carbone","doi":"10.34133/cancomm.0030","DOIUrl":"10.34133/cancomm.0030","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0030"},"PeriodicalIF":28.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EPO Receptor Blockade in Dendritic Cells Enhances Antitumor CD8⁺ T Cell Immunity.","authors":"Yunfei Zhu, Xuetao Cao","doi":"10.34133/cancomm.0027","DOIUrl":"10.34133/cancomm.0027","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0027"},"PeriodicalIF":28.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Grade-Specific Endoplasmic Reticulum Stress Vulnerabilities in Chondrosarcoma: Divergent Roles of Protein Kinase R-Like Endoplasmic Reticulum Kinase and Inositol-Requiring Enzyme 1α Signaling.","authors":"Hongtai Chen, Zezhuo Su, Ying Lee Lam, Raymond Ching Hin Yau, Anderson Siu Ming Leung, Gabriel Ching Ngai Leung, John Robert Honiball, Richard O C Oreffo, Jason Pui Yin Cheung, Siu Wai Choi, Kelvin Sin Chi Cheung","doi":"10.34133/cancomm.0026","DOIUrl":"10.34133/cancomm.0026","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0026"},"PeriodicalIF":28.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation.","authors":"Hui Zhang, Leirong Gu, Xiameng Su, Wanjin Chen, Ming Tan, Haibo Yu, Hongzhong Zhou, Tingting Gao, Zhiling Wang, Xinyan Chen, Weixian Chen, Juan Chen, Shengtao Cheng","doi":"10.34133/cancomm.0028","DOIUrl":"10.34133/cancomm.0028","url":null,"abstract":"<p><p><b>Background:</b> Metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC), and amino acid reprogramming plays an important role in its metastatic progression. However, the function of amino acid reprogramming in HCC metastatic progression remains unclear. This study aimed to elucidate the function and mechanism of amino acid reprogramming, particularly focusing on proline metabolism, in driving HCC metastasis. <b>Methods:</b> HCC cohort and multiple HCC models were enrolled to investigate the role of amino acid reprogramming in HCC metastatic progression. The pro-metastatic effect of l-proline in HCC was consistently validated across in vitro and in vivo studies. Ribosome profiling (Ribo-seq) and l-proline pull-down were used to investigate the mechanism of proline-mediated HCC metastasis. <b>Results:</b> Based on metabolomics and proteomics, we found that proline metabolism was enhanced during HCC metastasis, as evidenced by increased proline levels and proline metabolism-related enzymes in both HCC metastatic patients and mice. Moreover, high levels of proline were found to promote HCC metastasis. Mechanistically, l-proline directly interacted with glutamyl-prolyl-tRNA synthetase 1 (EPRS1) at its Glu¹¹²³ residue, thereby selectively enhancing the translation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA), AKT serine/threonine kinase 3 (AKT3), and integrin subunit β1 (ITGB1). Importantly, the enhanced protein translation could be abolished by bersiporocin, an EPRS1 inhibitor that prevents l-proline binding to EPRS1. Finally, the inhibitory effect of bersiporocin on HCC metastasis was confirmed in patient-derived orthotopic xenograft models. <b>Conclusions:</b> Our findings not only revealed the critical role of l-proline-bound EPRS1 in promoting HCC metastasis but also indicated that inhibiting this binding could be a promising strategy to prevent metastasis.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0028"},"PeriodicalIF":28.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}